AIS Healthcare is a leading provider of infusion care and targeted drug delivery or TDD. This healthcare provider operates in Mississippi, Alabama, Georgia, Florida, Texas and Maryland. The company has two state-of-the-art pharmacy compounding locations that aim to deliver the highest quality of prescription drug products to their many patients and doctors across the country. Recently, AIS Healthcare announced their expansion to several New England states that include Rhode Island, Massachusetts and Connecticut.

Just recently, AIS Healthcare was proud to receive one of the highest accreditations for Specialty Pharmacy divisions given by the prestigious URAC agency. This award will be in effect until 2025. The Chief Operations Officer for the healthcare company announced the news and verified that it pertained to 6 of its leading pharmacies. Along with this accreditation, the healthcare provider is also accredited by the Accreditation Commission for Health Care (ACHC) making it a dual accredited healthcare provider.

This premier healthcare provider recently celebrated its 15-year anniversary. The company was founded in Dallas, Texas, in 2008. Today, the company serves greater than 35,000 patients across several states. They specialize in advanced infusion therapy and targeted drug delivery. In addition, the company provides skilled nursing care to patients throughout the country. These highly trained nurses and other staff members provide top-quality care services to patients who often have complex health conditions like genetic conditions that cause immunodeficiency’s among other issues.

The company is led by a well-trained and experienced team of executives who supervise and run the business side of the operations. They are committed to providing both quality services to their patients and are there to fully support their valued team of pharmacists, nurses and other healthcare providers within their system. Their mission is to improve the lives of both patients and the providers that they serve.

In May of 2023, AIS was showcased in a case study documented in the National Home Infusion Association’s own Infusion Journal. The results from this study have been most promising. The study documents a patient with chronic variable immunodeficiency (CVID)who has chosen therapy via the company’s immune globulin (Ig) therapy with good results.